Pharma Zentrale Gmbh, Herdecke

What Pharma Zentrale Gmbh, Herdecke does

Pharma-Zentrale GmbH, founded in 1953 and headquartered in Herdecke, North Rhine-Westphalia, Germany, is a privately held family-owned German group of pharmaceutical and biotechnological companies. The group operates through the parent entity and four wholly-owned subsidiaries — BBT Biotech (biological APIs via fermentation), Ardeypharm (probiotic drugs with particular expertise in Escherichia coli strain Nissle 1917), Dr. Poehlmann & Co. (natural-origin OTC drugs and tonics), and Dr. Ponsold Pharma (veterinary probiotic drugs). The company is continuously GMP-certified under EU Directive 2003/94/EC and conducts fermentation under Part II of EU-GMP guidelines.

The group's core technology is fermentation-based production of biological active pharmaceutical ingredients (viable bacteria and yeasts), combined with full-service manufacturing of finished pharmaceutical products including tablets, capsules, and liquids. Beyond captive product lines, Pharma-Zentrale offers GMP-compliant contract manufacturing services to biotechnology and pharmaceutical companies globally, covering APIs, dosage forms, pharmaceutical products, and food supplements.

The company monetizes through three primary channels: contract manufacturing services for biotech and pharma clients, direct sale of biological APIs internationally, and export of pharmaceutical bulk goods and finished products. Customer segments are horizontal — primarily biotechnology companies requiring GMP-certified biological manufacturing and pharmaceutical companies seeking probiotics, biological APIs, and bulk pharmaceutical supply. The company's commercial reach is global, with direct export to customers across multiple continents and industry event participation (e.g., the 2019 Microbiome International Expert Summit in Bangkok).

Name

Pharma Zentrale Gmbh, Herdecke

Legal name

Pharma-Zentrale GmbH

Website

https://pharma-zentrale.de

Company type

Private

Founded year

1953

Operating status

Operating

Headcount range

1–10 employees

Short description

Pharma-Zentrale GmbH is a German family-owned pharmaceutical group founded in 1953, specializing in probiotic and phyto-pharmaceuticals, biological API production via fermentation, and GMP-certified contract manufacturing for biotechnology and pharmaceutical companies globally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM)

akta.pro secondary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Contract pharmaceutical manufacturing
• Biological API production
• Probiotic pharmaceuticals
• GMP-certified manufacturing
• Phyto-pharmaceutical products

Headquarters

HQ city

Herdecke

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: GMP-compliant contract manufacturing services for biotechnology and pharmaceutical industry covering APIs, dosage forms (tablets, capsules, liquids), pharmaceuticals and food supplements. Full-service production from API fermentation through finished product packaging.
2. API Sales: Sale of biological APIs including highly purified active pharmaceutical ingredients of biological origin, viable bacteria and yeasts as international offering in API or dosage forms.
3. Finished Products Export: Export of pharmaceutical bulk (liquid, semi-solid and solid forms) and finished products to international markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Pharma-Zentrale develops probiotic and phyto-pharmaceuticals, produces biological active pharmaceutical ingredients (APIs) through fermentation, and offers GMP-certified contract manufacturing services for the biotechnology and pharmaceutical industry. The company provides full-service production from API fermentation through mixing with excipients, encapsulation, bottling, and packaging of finished dosage forms including tablets, capsules, and liquids.

Product overview

Pharma-Zentrale is a German group of companies founded in 1953, operating as a family business with five pharmaceutical and biotechnological subsidiaries. The group specializes in probiotic and phyto-pharmaceuticals, biological APIs, and GMP-certified contract manufacturing. The portfolio includes Pharma-Zentrale (core GMP manufacturing and contract services), BBT Biotech (biological APIs via fermentation), Ardeypharm (probiotic drugs and E. coli strain Nissle 1917), Dr. Poehlmann & Co (natural OTC products), and Dr. Ponsold-Pharma (veterinary probiotic drugs). Services span from API production through fermentation to finished dosage forms including tablets, capsules, and liquids.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Manufacturing Services GMP-compliant contract manufacturing services for biotechnology and pharmaceutical companies covering APIs, dosage forms (tablets, capsules, liquids), pharmaceuticals, and food supplements. Full-service production from API fermentation through finished product packaging.
• Biological APIs (via BBT Biotech) Highly purified active pharmaceutical ingredients of biological origin, including viable bacteria and yeasts, produced through purification and fermentation processes and offered internationally as APIs or dosage forms.
• Probiotic Drugs (via Ardeypharm) Probiotic drugs for the gastrointestinal tract, herbal remedies, and chemically defined drugs, with strong expertise in development and commercialisation of Escherichia coli strain Nissle 1917.
• Natural OTC Products (via Dr. Poehlmann & Co.) Drugs and tonics of natural origin, offering over-the-counter (OTC) pharmaceutical products.
• Veterinary Probiotic Drugs (via Dr. Ponsold-Pharma) Animal health products and veterinary probiotic drugs.
• Pharmaceutical Bulk Export Export of pharmaceutical bulk goods in liquid, semi-solid, and solid forms, along with finished products to international markets.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• BBT BiotechcoreOthersSubsidiary within the German Group of Companies specializing in highly purified APIs of biological origin, viable bacteria and yeasts, purification and fermentation services. International offering as API or dosage forms.
• ArdeypharmcoreOthersSubsidiary specializing in probiotic drugs for the gastrointestinal tract, herbal remedies and chemically defined drugs. Strong track record in development and commercialisation of Escherichia coli strain Nissle 1917.
• Dr. Poehlmann & Co.minorOthersSubsidiary specializing in drugs and tonics of natural origin and OTC products.
• Dr. Ponsold PharmaminorOthersSubsidiary specializing in animal health products and veterinary probiotic drugs.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• BioGaia: Swedish probiotic products company developing and commercializing Lactobacillus reuteri strains for gastrointestinal and immune health. Directly comparable to Pharma-Zentrale's probiotic drug franchise via Ardeypharm, with similar B2B pharma/nutraceutical customer model.
• Lallemand Health Solutions: Canadian probiotic manufacturer producing probiotic strains and formulations for the human health and nutrition market. Comparable to Pharma-Zentrale in fermentation-based probiotic strain production and international B2B supply.
• Winclove Probiotics: Dutch probiotic manufacturer specializing in multi-strain probiotic formulations for clinical and over-the-counter applications. Comparable in probiotic formulation development and GMP manufacturing for pharmaceutical-grade and supplement markets.
• Probi AB: Swedish probiotics manufacturer developing clinically documented probiotic strains for therapeutic and consumer health applications. Comparable to Pharma-Zentrale in probiotic strain development, fermentation manufacturing, and B2B supply model.

Emerging players

• AB Biotics: Spanish biotech developing proprietary probiotic strains for pharmaceutical and nutraceutical applications. Comparable to Pharma-Zentrale in developing and commercializing clinically documented probiotic strains, though focused on its own brand commercialization rather than CDMO services.

Broad incumbents

• WuXi Biologics: Chinese contract development and manufacturing organ for biologics, including microbial fermentation services. Comparable to Pharma-Zentrale in fermentation-based biological API contract manufacturing, but operates at significantly greater scale globally.
• Lonza Group: Swiss global CDMO providing mammalian and microbial fermentation services for pharmaceutical APIs and biologics. Comparable to Pharma-Zentrale in fermentation-based contract manufacturing for pharma, but operates at industrial scale with a much broader service portfolio.
• Novonesis (formerly Chr. Hansen): Global bioscience company producing enzymes, probiotics, and fermentation-based ingredients for pharma, food, and agriculture. Overlaps with Pharma-Zentrale in fermentation-based probiotic API production but at vastly greater scale and across broader end markets.
• Catalent: Global CDMO offering development and manufacturing services for biologics, oral and inhaled dosage forms. Comparable to Pharma-Zentrale in contract manufacturing of finished dosage forms (tablets, capsules) but at much larger scale and across multiple therapeutic areas.
• dsm-firmenich: Global nutrition and health company producing vitamins, APIs, and probiotic ingredients through i-Health. Comparable to Pharma-Zentrale in producing biological probiotic ingredients and APIs, but operates at much larger scale across multiple nutrition categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/pharma-zentrale-gmbh-herdecke

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Zentrale Gmbh, Herdecke